Medikine

Medikine is a private, preclinical-stage biotech developing a new class of cytokine mimetic drugs called PEPTIKINES. Its proprietary discovery platform enables the creation of small, structurally unrelated peptide agonists that can be engineered for optimized pharmacokinetics, reduced immunogenicity, and improved therapeutic windows compared to natural cytokines. The company's lead candidate, MDK-703, is an IL-7 mimetic aimed at immuno-oncology, with a pipeline targeting oncology, autoimmune disorders, and infectious diseases. Backed by experienced founders and venture capital, Medikine seeks to translate its validated platform technology into transformative therapies.

Proprietary platform using peptide library screening, combinatorial synthetic peptide ligation chemistry, and protein engineering to discover and optimize small peptide 'PEPTIKINES' that mimic cytokine activity. The platform designs structurally unrelated peptide agonists that can be engineered for improved pharmacokinetics, reduced immunogenicity, and optimized therapeutic windows.

Medikine competes with companies developing engineered natural cytokines (e.g., Fc-fusions, PEGylated versions), antibody-cytokine fusions (immunocytokines), and other cytokine mimetic approaches. Large biopharma firms with major immunology portfolios are also key competitors. Medikine's differentiation lies in its structurally novel, de novo designed peptide agonists that aim for lower immunogenicity and greater engineerability than modified natural proteins.